Peter Greenleaf currently serves as the Chief Executive Officer and member of the Board of Directors of Aurinia. From March 2018 to April 2019, Peter served as the Chief Executive Officer of Cerecor, Inc. From March 2014 to February 2018, Peter served as CEO and Chairman of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP). Sucampo was focused on the development and commercialization of medicines to meet major unmet medical needs of patients worldwide and was sold in February 2018 to UK pharmaceutical company Mallinckrodt PLC. From June 2013 to March 2014, Peter served as CEO and a member of the Board of Directors of Histogenics Corporation, a regenerative medicine company. From 2006 to 2013, he was employed by Medlmmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. From January 2010 to June 2013, Peter also served as President of Medlmmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group. Prior to serving as President of Medlmmune, Peter was Senior Vice President, Commercial Operations of the company, responsible for its commercial, corporate development, and strategy functions. He has also held senior commercial roles at Centocor, Inc. (now Jansen Biotechnology, Johnson & Johnson) from 1998 to 2006 and at Boehringer Mannheim (now Roche Holdings) from 1996 to 1998. Peter currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of Invest Maryland, a public-private partnership to spur venture capital investment in the state. He is also currently a member of the Board of Directors of Antares Pharmaceuticals, Inc. (NASDAQ: ATRS) and Chairman of the Board of Directors of Biodelivery Sciences International, Inc. (NASDAQ: BDSI). Peter earned an MBA from St. Joseph's University and a B.S. from Western Connecticut State University.
Peter’s significant executive management, leadership, corporate development, and commercial operations experience in the biopharmaceutical industry enables him to provide valuable insight to our Board of Directors.
What is Peter Greenleaf's net worth?
The estimated net worth of Peter Greenleaf is at least $4.79 million as of March 2nd, 2023. Mr. Greenleaf owns 982,968 shares of Aurinia Pharmaceuticals stock worth more than $4,787,054 as of April 26th. This net worth estimate does not reflect any other assets that Mr. Greenleaf may own. Additionally, Mr. Greenleaf receives a salary of $1,340,000.00 as CEO at Aurinia Pharmaceuticals. Learn More about Peter Greenleaf's net worth.
How old is Peter Greenleaf?
What is Peter Greenleaf's salary?
How do I contact Peter Greenleaf?
Has Peter Greenleaf been buying or selling shares of Aurinia Pharmaceuticals?
Peter Greenleaf has not been actively trading shares of Aurinia Pharmaceuticals within the last three months. Most recently, Peter Greenleaf sold 32,750 shares of the business's stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $8.94, for a transaction totalling $292,785.00. Following the completion of the sale, the chief executive officer now directly owns 982,968 shares of the company's stock, valued at $8,787,733.92. Learn More on Peter Greenleaf's trading history.
Who are Aurinia Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Aurinia Pharmaceuticals?
In the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 9,005 shares worth more than $101,211.34. The most recent insider tranaction occured on May, 23rd when Director David R.W. Jayne sold 8,733 shares worth more than $98,333.58. Insiders at Aurinia Pharmaceuticals own 4.3% of the company.
Learn More about insider trades at Aurinia Pharmaceuticals. Information on this page was last updated on 5/23/2023.
